| Project/Area Number |
26860121
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Sojo University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 一酸化炭素 / ヘモグロビン / リポソーム / 肺 / 敗血症 / 輸血関連急性肺傷害 |
|---|
| Outline of Final Research Achievements |
Carbon monoxide (CO) has potent anti-inflammatory, anti-oxidant and anti-virus effects. We prepare a CO-bound hemoglobin-vesicles (CO-HbV), and evaluated the possibility that CO-HbV has a potential to suppress both infection and multi-organ failure. As a result, CO-HbVs administration increased the survival rate in cecum ligation and puncture model mice, a sepsis model, compared to HbV administration. In addition, HbV as well as freshly packed RBC was less predisposed to result in a post-transfusion lung injury than stored packed RBC. Furthermore, CO-HbV also ameliorated multi-organ injuries (liver, kidneys, lungs and pancreas) induced by severe acute pancreatitis in mice. Taken together with these results, CO-HbV has the potential for use in the treatment of massive hemorrhage with anti-infection and cytoprotective effects.
|
